Quest PharmaTech Inc (QPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quest PharmaTech Inc (QPT) has a cash flow conversion efficiency ratio of -0.002x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-35.00K ≈ $-25.32K USD) by net assets (CA$23.08 Million ≈ $16.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Quest PharmaTech Inc (QPT) balance sheet quality index to measure how much of total assets are equity-financed.
Quest PharmaTech Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Quest PharmaTech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Quest PharmaTech Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Quest PharmaTech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quest PharmaTech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Palatin Technologies Inc
NYSE MKT:PTN
|
0.838x |
|
Netcall plc
LSE:NET
|
0.012x |
|
BLACK PEARL ZY-10
F:7ZX
|
-0.011x |
|
Creative Medical Technology Holdings Inc
NASDAQ:CELZ
|
-0.216x |
|
Alpha Star Acquisition Corp
NASDAQ:ALSA
|
0.032x |
|
GRI Bio Inc.
NASDAQ:GRI
|
-0.349x |
|
Ocean Sun As
OL:OSUN
|
-0.298x |
|
NEXTLEAF SOLUTIONS
F:L0MA
|
0.072x |
Annual Cash Flow Conversion Efficiency for Quest PharmaTech Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Quest PharmaTech Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Quest PharmaTech Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | CA$21.40 Million ≈ $15.48 Million |
CA$-511.88K ≈ $-370.28K |
-0.024x | -61.77% |
| 2024-01-31 | CA$23.15 Million ≈ $16.75 Million |
CA$-342.42K ≈ $-247.70K |
-0.015x | -121.97% |
| 2023-01-31 | CA$83.25 Million ≈ $60.22 Million |
CA$-554.68K ≈ $-401.25K |
-0.007x | -252.71% |
| 2022-01-31 | CA$90.41 Million ≈ $65.40 Million |
CA$-170.78K ≈ $-123.54K |
-0.002x | +86.84% |
| 2021-01-31 | CA$175.22 Million ≈ $126.75 Million |
CA$-2.52 Million ≈ $-1.82 Million |
-0.014x | -103.71% |
| 2020-01-31 | CA$-16.50 Million ≈ $-11.93 Million |
CA$-6.38 Million ≈ $-4.61 Million |
0.387x | -75.75% |
| 2019-01-31 | CA$-4.33 Million ≈ $-3.14 Million |
CA$-6.91 Million ≈ $-5.00 Million |
1.594x | +161.66% |
| 2018-01-31 | CA$2.83 Million ≈ $2.05 Million |
CA$-7.33 Million ≈ $-5.30 Million |
-2.584x | -496.23% |
| 2017-01-31 | CA$10.63 Million ≈ $7.69 Million |
CA$-4.61 Million ≈ $-3.33 Million |
-0.433x | -141.22% |
| 2016-01-31 | CA$-2.43 Million ≈ $-1.76 Million |
CA$-2.56 Million ≈ $-1.85 Million |
1.052x | +102.15% |
| 2015-01-31 | CA$-3.73 Million ≈ $-2.70 Million |
CA$-1.94 Million ≈ $-1.41 Million |
0.520x | -35.94% |
| 2014-01-31 | CA$-2.41 Million ≈ $-1.75 Million |
CA$-1.96 Million ≈ $-1.42 Million |
0.812x | +420.61% |
| 1998-01-31 | CA$322.79K ≈ $233.50K |
CA$-81.77K ≈ $-59.15K |
-0.253x | -- |
About Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.